Vascepa Efficacy Evaluated in Statin-Treated Women with High TG

Results showed that icosapent ethyl significantly reduced TGs (–22%; P<0.0001) compared with placebo
Results showed that icosapent ethyl significantly reduced TGs (–22%; P<0.0001) compared with placebo

Icosapent ethyl (Vascepa; Amarin) demonstrates a reduction in triglyceride levels and several other potentially atherogenic lipid parameters in women with high trigylcerides who are taking statins. The findings come from a new post-hoc analysis of the ANCHOR study, which was presented at the American Heart Association Scientific Sessions 2016.

Icosapent ethyl (Vascepa; Amarin) demonstrates a reduction in triglyceride levels and several other potentially atherogenic lipid parameters in women with high trigylcerides (TG) who are taking statins. The findings come from a new post-hoc analysis of the ANCHOR study, which was presented at the American Heart Association Scientific Sessions 2016. 

Related Articles

The post-hoc analysis of ANCHOR included 179 women taken from the overall study population of 702. The efficacy of icosapent ethyl (Vascepa) on TG levels, atherogenic (lipid and lipoprotein) parameters and inflammatory markers was evaluated among this subgroup. They were randomized to receive either icosapent ethyl 4g/day (n=91) or placebo (n=88) from baseline to week 12. 

Results showed that icosapent ethyl significantly reduced TGs (–22%; P<0.0001) compared with placebo, without increasing LDL-C (—6%; P>0.05). Significant improvement in other potentially atherogenic parameters (non-HDL-C, VLDL-C, VLDL-TG, apoB, RLP-C) and inflammatory markers (Ox-LDL, Lp-PLA2, hsCRP) were also observed vs. placebo (P<0.05 for all).

Amarin is currently investigating Vascepa in the REDUCE-IT trial. REDUCE-IT is a global Phase 3, randomized, multicenter, double-blind, placebo-controlled study. Its purpose is to evaluate whether treatment with Vascepa reduces cardiovascular events in patients who despite stabilized statin therapy have elevated triglyceride levels and other cardiovascular risk factors.

Speaking about the latest post-hoc analysis, Lori Mosca, MD, MPH, PhD, and lead author, said, “This analysis is encouraging because the efficacy and safety of Vascepa 4g/day in this subgroup of 91 statin-treated women with persistent high triglycerides were consistent with the overall ANCHOR results, which included 702 patients.”

Vascepa is FDA-approved as an adjunct to diet to reduce TG levels in adult patients with severe (≥500mg/dL) hypertriglyceridemia.

The analysis was presented at the American Heart Association Scientific Sessions in New Orleans.

For more information visit ajconline.com.

Loading links....